

NW2

July 2020 - June 2025

	n	Ampicillin	Ampicillin-Sulbactam	Aztreonam	Cefazolin	Cefepime	Ceftazidime	Ceftriaxone	Ciprofloxacin	Clindamycin	Daptomycin <sup>2</sup>	Gentamicin	Levofloxacin	Linezolid	Meropenem	Nitrofurantoin <sup>3</sup>	Oxacillin	Penicillin G	Piperacillin-Tazobactam	Tetracycline	Tobramycin	Trimethoprim-Sulfamethoxazo	Vancomycin
Gram Negative	Acinetobacter baumannii complex <sup>1</sup>	2		1		1		1	1			1			1				1		1	1	
	Enterobacter cloacae <sup>1</sup>	18			61%	72%		61%	61%			94%			94%	1			61%		94%	67%	
	Escherichia coli	90	20%	23%	68%	40%	67%	68%	23%			81%			99%	100%			62%		72%	46%	
	Klebsiella pneumoniae	40		43%	58%	43%	58%	55%	53%			70%			95%	41%			50%		60%	53%	
	Proteus mirabilis <sup>1</sup>	8	1	1	1	1	1	1	1			1							1		1	1	
	Pseudomonas aeruginosa <sup>1</sup>	22			79%		85%		81%			96%			86%				86%		95%		
	Serratia marcescens <sup>1</sup>	5			1	1		1	1			1			1				1		1	1	
	Stenotrophomonas maltophilia <sup>1</sup>	6					1						1									1	

Gram Positive	Staphylococcus aureus	36			56%				76%			90%				57%	0%		93%		88%	100%
	Staphylococcus epidermidis	55			10%				35%			77%				10%	0%		80%			100%
	Other Coag-Negative Staphylococcus	37			39%				35%			54%				38%	0%		70%			100%
	Streptococcus mitis/oralis	17					88%										31%				100%	
	Enterococcus faecalis <sup>1</sup>	22	100%									86%									82%	
	Enterococcus faecium	62	3%						95%			98%									16%	

Denotes antibiotics that are not routinely tested against or known to be clinically relevant treatment options for the specific organisms

KEY

10<sup>+</sup> % decrease in susceptibility from 2018-2023 antibiogram

10<sup>+</sup> % increase in susceptibility from 2018-2023 antibiogram

10<sup>+</sup> % decrease in susceptibility compared to global inpatient population

10<sup>+</sup> % increase in susceptibility compared to global inpatient population

1

Organisms with fewer than 30 isolates should be interpreted with caution as small numbers may bias group susceptibilities

2

For *E. faecalis*, daptomycin is not recommended due to cost and the availability of an agent with a narrower spectrum of activity

3

For treatment of uncomplicated urinary tract infection with CrCl > 30mL/min only

All Moses

July 2020 - June 2025

	n	Ampicillin	Ampicillin-Sulbactam	Aztreonam	Cefazolin	Cefepime	Ceftazidime	Ceftriaxone	Ciprofloxacin	Clindamycin	Daptomycin <sup>2</sup>	Gentamicin	Levofloxacin	Linezolid	Meropenem	Nitrofurantoin <sup>3</sup>	Oxacillin	Penicillin G	Piperacillin-Tazobactam	Tetracycline	Tobramycin	Trimethoprim-Sulfamethoxazol	Vancomycin
Gram Negative	Acinetobacter baumannii complex	321		56%		35%		21%	35%			47%			40%				38%		64%	48%	
	Enterobacter cloacae	624			65%	80%		61%	79%			93%			94%	39%			64%		91%	83%	
	Escherichia coli	5521	36%	42%	79%	58%	80%	78%	54%			85%			99%	96%			75%		83%	63%	
	Klebsiella pneumoniae	2507		59%	75%	62%	76%	74%	71%			91%			97%	52%			69%		87%	73%	
	Proteus mirabilis	1040	65%	76%	87%	2%	90%	86%	70%			79%							86%		80%	78%	
	Pseudomonas aeruginosa	2028			73%		86%		78%			95%			86%				77%		95%		
	Serratia marcescens	391			85%	94%		81%	81%			94%			98%				82%		61%	95%	
	Stenotrophomonas maltophilia	320					35%						72%									96%	

Gram Positive	Staphylococcus aureus	3402			58%			76%			97%				58%	0%		85%		91%	100%
	Staphylococcus epidermidis	1511			31%			48%			82%				31%	0%		79%			100%
	Other Coag-Negative Staphylococcus	985			55%			60%			80%				55%	0%		77%			100%
	Streptococcus mitis/oralis	57					91%									40%					98%
	Enterococcus faecalis	1055	99%									98%									93%
	Enterococcus faecium	566	8%						96%			95%									30%